Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Biogen

Growth in the quarter was driven by MS revenues, which increased 5%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen
2Q Revenues: $3.1 billion (+6%)
2Q Earnings: $863 million (-18%)
YTD Revenues: $5.9 billion (+5%)
YTD Earnings: $1.6 billion (-20%)
Comments: Growth was driven by MS revenues, which increased 5%. This included a 13% increase in TECFIDERA to $1.1 billon. SPINRAZA revenues grew to $203 million and BENEPALIT revenues increased to $89 million in the quarter. Avonex sales were down 8% to $691 million. Tysabri sales were flat at $496 million. Plegridy sales were $133 million, up 8%. Biosimilar sales were $91 million in the quarter, up from $15 million 2Q16. In 1Q17, Biogen completed the separation of its global hemophilia business into a new company, known as Bioverativ. The 15% increase in total revenues excludes all hemophilia revenues from 2Q16. Hemophilia revenues include ELOCTATE and ALPROLIX product revenues as well as royalty and contract manufacturing revenue related to Sobi.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters